Filgrastim (Neupogen, Granix, Nivestym, Zarxio)

Other Medications · Approved since 1991

US FDA Approved EU med_ema_approved ES med_spain_hospital_use med_crc_other_indication Subcutaneous, IV 8 Clinical Trials
G-CSF receptor (CSF3R)

Description

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) used as supportive care in colorectal cancer patients receiving myelosuppressive chemotherapy. It stimulates the production and release of neutrophils from the bone marrow to prevent or treat chemotherapy-induced neutropenia. In CRC treatment, filgrastim allows patients to maintain scheduled chemotherapy dosing and reduces the risk of febrile neutropenia during intensive treatment regimens.

Mechanism of Action

Filgrastim binds to G-CSF receptors on neutrophil precursor cells and mature neutrophils in the bone marrow. This binding activates intracellular signaling pathways that promote neutrophil proliferation, differentiation, and release from the bone marrow into peripheral circulation, while also enhancing neutrophil survival and function.

Molecular Targets

Side Effects

Bone pain Headache Fatigue Nausea Injection site reactions Muscle aches Splenomegaly Transient increases in lactate dehydrogenase

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06504901 Not Applicable
Not yet recruiting
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
NCT02650635 med_phase_prefix1
Archived
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
United States
NCT01059643 med_phase_prefix2
Archived
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
United States
NCT00911170 med_phase_prefix3
Archived
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Hungary, I
NCT00541125 med_phase_prefix2
Archived
G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
NCT00557102 med_phase_prefix2
Archived
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
France
View all 8 clinical trials →

Quick Info

Brand NameNeupogen, Granix, Nivestym, Zarxio
CategoryOther Medications
US StatusFDA Approved
EU Estado EMAmed_ema_approved
ES Acceso Españamed_spain_hospital_use med_crc_other_indication
AdministrationSubcutaneous, IV
Year Approved1991
Clinical Trials8
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.